MedTrace Logo

Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia

NCT01533168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2016-05-18

No results posted yet for this study

Summary

RATIONALE: Testing for minimal residual disease in cell samples from patients with acute lymphoblastic leukemia may help doctors plan better treatment.

PURPOSE: This research trial studies a genetic test in identifying previously undetectable minimal residual disease in cell samples from younger patients with acute lymphoblastic leukemia.

Conditions

Interventions

GENETIC

cytogenetic analysis

GENETIC

nucleic acid sequencing

OTHER

diagnostic laboratory biomarker analysis

OTHER

laboratory biomarker analysis

OTHER

medical chart review

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Norman J. Lacayo, MD · Stanford University

Eligibility

Min Age
1 Year
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2016-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01533168 on ClinicalTrials.gov